Lords Mark

Lords Mark has evolved from a paper manufacturer into a dynamic conglomerate driving innovation across diagnostics, MedTech, renewable energy and electric mobility.The company leverages strategic diversification to capitalize on India’s sustainability and healthcare megatrends. The company is poised for a reverse merger with Kratos Energy to list on BSE within 90–120 days, accelerating its vision to become a globally recognized brand.

Core Products and Services

• Diagnostics & MedTech: Rapid test kits (ICMR-approved), biochemistry reagents, and AI-powered remote patient monitoring systems.

• Renewable Energy: Rooftop solar EPC projects for government/schools. Defense-grade LED lighting (e.g., INS Vikramaditya warship).

• Paper & Industrial: BIS-certified continuous stationery for railways, postal services, and government depots.

• EV & Future Tech: Electric scooters under Lords Automative; genome testing via Lords Mark Biotech.

Business Model & Revenue Streams

• MedTech/IVD: 41% (₹228 Cr), driven by tender-based government contracts and exports.

• Renewable Energy/LED: 41% (₹228 Cr), anchored by UPNEDA solar projects.

• Paper: 18% (₹100 Cr), with phased divestment underway.

• Geographic Reach: India-centric (95% revenue), with US/EU expansion targeting 30% revenue by 2027.

Customer segmentation

• B2G: 70% revenue from government tenders (solar, railways, defense).

• B2B: Distribution via JVs (e.g., Braithwaite & Co for railway hospitals).

• B2C: Limited via health kiosks and EV sales.

Top Clients & Partnerships

• Governments: UPNEDA, Punjab Energy, Assam Power (₹1,587 Cr order book for solar/LED).

• Braithwaite & Co: 5-year JV for supplying MedTech to Indian Railways.

• Dozee: AI-patient monitoring distribution in public hospitals.

• Cipla Healthcare: OTC product distribution pan-India.

• Defense & Infrastructure: Indian Navy (warship lighting), Philips India (solar lighting).

Future Outlook & Strategic Priorities

• Global MedTech Push: Replicate US entry in EU/Australia; target $50M exports by 2027.

• Renewables Scale-Up: Execute ₹1,415 Cr solar order book over 5 years.

• EV & Biotech: Launch next-gen e-scooters; expand genome testing for preventive care.

• Margin Pressure: Low-bid solar tenders (₹4.80/unit) and MedTech import costs.

• Regulatory Hurdles: FDA/CE certifications for global MedTech expansion.